New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 20, 2014
14:11 EDTTKMRTekmira lipid nanoparticle targeting Marburg virus highlighted in journal
Tekmira Pharmaceuticals announced the publication of data in a peer-reviewed scientific journal which highlights positive results in an animal model of Marburg virus infection enabled by Tekmira's lipid nanoparticle technology. Tekmira, along with its collaborators at the University of Texas Medical Branch at Galveston, USA, published data demonstrating complete protection of nonhuman primates against lethal Marburg virus-Angola hemorrhagic fever when treatment began even up to three days following infection. The study appears in the August 20 edition of the journal Science Translational Medicine. The study was designed to determine whether it is possible to protect animals against a lethal MARV-Angola infection when treatment was started at a point when animals have detectable levels of the virus in their system and already show the first clinical signs of disease.
News For TKMR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 19, 2015
14:33 EDTTKMRTekmira main driver still hepatitis B program, says Leerink
Subscribe for More Information
09:18 EDTTKMROn The Fly: Pre-market Movers
Subscribe for More Information
08:01 EDTTKMRTekmira provides update on TKM-Ebola-Guinea
Tekmira Pharmaceuticals announced that the Phase II clinical trial of TKM-Ebola-Guinea has reached a predefined statistical endpoint and enrollment has been closed. The endpoint indicated that continuing enrollment was not likely to demonstrate an overall therapeutic benefit. Data analysis is ongoing and the full results will be made available as soon as possible. In this trial, TKM-Ebola-Guinea is being evaluated for efficacy in Ebola virus infected patients in Sierra Leone, West Africa. The Phase II single arm trial called RAPIDE, or Rapid Assessment of Potential Interventions & Drugs for Ebola, is open-label with a concurrent observational study of Ebola virus disease in Sierra Leone.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use